An independent marijuana reform legislation has been sent to the desk of the President of the United States for the first time. The "Medical Marijuana and Cannabinoid Research Expansion Act" is just one step away from historic legislation.
Just a few weeks after President Joe Biden announced a large-scale marijuana pardon and instructed a review of the drug's scheduling status, the US Senate on Wednesday approved a bipartisan marijuana research bill passed by the House of Representatives.
Senate Majority Leader Chuck Schumer has stated that he will continue to hold "productive conversations" regarding broader marijuana reform. According to Marijuana Moments, he hopes to pass these reforms before the current congressional session comes to a close.
Before the vote, Schumer stated that the bill "will eliminate red tape that impedes marijuana research and open the doors for innovative new therapies derived from marijuana." "If you are one of the millions of Americans suffering from Parkinson's, epilepsy, post-traumatic stress disorder, or any other illness, marijuana may offer promising new options for treatment.
We need to conduct research first," he said. "Unfortunately, the federal government is severely lagging behind in this area. This bill will help address this issue.
At a recent meeting, each chamber presented and advanced a number of marijuana measures. However, reform has stalled before reaching the president.
The bill was submitted in July and quickly passed in the House of Representatives, before being reviewed by the Senate, which approved the legislation unanimously.
Statement:
This article is a compilation of information obtained from third-party sources and is intended solely for industry professionals for exchange and learning purposes.
This article does not represent the viewpoint of 2FIRSTS and 2FIRSTS cannot confirm the authenticity and accuracy of the article's content. The translation of this article is only intended for industry research and communication purposes.
Due to limitations in the translation skills, the translated article may not fully reflect the original text. Please refer to the original article for accuracy.
2FIRSTS aligns with the Chinese government's stance on all domestic, Hong Kong, Macau, Taiwan, and foreign-related issues and statements.
The copyright of the compiled information belongs to the original media and author. If there is any infringement, please contact us for removal.
This document has been generated through artificial intelligence translation and is provided solely for the purposes of industry discourse and learning. Please note that the intellectual property rights of the content belong to the original media source or author. Owing to certain limitations in the translation process, there may be discrepancies between the translated text and the original content. We recommend referring to the original source for complete accuracy. In case of any inaccuracies, we invite you to reach out to us with corrections. If you believe any content has infringed upon your rights, please contact us immediately for its removal.
